Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases

Abstract

An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.

1 . A pharmaceutical composition, comprising an adequate pharmaceutical carrier or diluent a glycosaminoglycan—an effective amount of a compound activating an alpha 2 adrenergic receptor agonist for use in the treatment and/or the prevention of acute or chronic osteoarticular diseases and/or symptoms by intra-articular injection. 
     
     
         2 . The composition of  claim 1 , wherein the acute or chronic osteoarticular symptom is selected from the group consisting of pain, loss of mobility and/or function. 
     
     
         3 . The pharmaceutical composition according to the  claim 1 , wherein the alpha 2 adrenergic receptor agonist is selected from the group consisting of clonidine, p-aminoclonidine, tiamenidine, 5-bromo-6-(2 imidazolidine-2-ylamino)quinoxaline, dexmedetomidine, detomidine, medetomidine, oxymetazonline, tizanidine, mivazerol, lofexidine, xylazine, guanfacine, guanclofine, guanoxabenz, or a derivative or structural analogue thereof, alpha-methylnorepherine, azepexole, indoramin, 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine diHCl. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein the glycosaminoglycan is present as a glycosaminoglycan based hydrogel and wherein the glycosaminoglycan and the compound activating the alpha 2 adrenergic receptor are or are not covalently linked. 
     
     
         5 . The pharmaceutical composition according to  claim 1 , wherein the glycosaminoglycan is selected from the group consisting of a proteoglycan, a chondroitin sulphate, a keratin sulphate or a hyaluronic acid or its derivative, a chitosan, a chitosan or chitin derivative or a mixture thereof. 
     
     
         6 . The pharmaceutical composition according to  claim 1  which is an injectable solution. 
     
     
         7 . The pharmaceutical composition according to  claim 1 , which comprises from 0.1 to 100 mg/kg of body weight of glycosaminoglycan and from 0.1 μg to 1 mg of compound. 
     
     
         8 . The pharmaceutical composition according to  claim 1 , wherein the osteoarticular disease is selected from the group consisting of osteoarthritis, degenerative arthritis, gonarthrosis, coxarthrosis, and other inflammatory general conditions or symptoms in which joints are involved, such as systemic lupus erythematosus, spondyloarthropathies, polymyalgia rheumatica, ankylosing spondylitis, Reiter's Syndrome, psoriatic arthropathy, enteropathic arthritis (related to inflammatory bowel disease such as haemorrhagic colitis and Crohn's) disease, rheumatoid arthritis, neuropathic arthropathy, acute rheumatic fever, gout, chondrocalcinosis, calcium hydroxyapatite crystal deposition disease, and Lyme disease. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the injection is done once in two or more weeks. 
     
     
         10 . The pharmaceutical composition of  claim 1  further containing another anti-inflammatory compound. 
     
     
         11 . The pharmaceutical composition of  claim 1  further containing human adult mesenchymal stem cells or non human embryonic mesenchymal stem cells. 
     
     
         12 . A composition comprising possibly an adequate pharmaceutical carrier or diluent 0.1 to 100 mg/kg of body weight of a glycosaminoglycan 0.1 μg to 1 mg of a compound activating the alpha 2 adrenergic receptor. 
     
     
         13 . A kit of parts comprising a vial with the composition according to  claim 1 , a device for delivering said composition to an inflamed joint of a mammal subject and having reservoir means for storing said composition, piston means movable along the longitudinal axis of the reservoir for dispensing said pharmaceutical composition, and an hollow needle mounted on said reservoir means for delivering said pharmaceutical composition to the peripheral nerve of the mammal subject.